Amgen to Colorado: Cap This!
In a stunning display of bureaucratic bravado, the Colorado Prescription Drug Affordability Review Board has decided to take on the pharmaceutical giant Amgen by capping the price of Enbrel, an immunosuppressant drug that has seen its price balloon over 1,500% since its launch in the late '90s. This noble endeavor to save Coloradans from financial ruin is now thwarted by a federal court ruling that has effectively told Colorado to take a seat and mind its own business when it comes to drug pricing. Apparently, the only thing more inflated than the price of Enbrel is the ego of Big Pharma. The courtโs preliminary injunction against the cap suggests that the federal government believes Amgen needs to continue raking in profits rather than allowing ordinary citizens access to affordable medication. After all, who needs health when the pharmaceutical industry is busy counting their billions? The ruling relies on the doctrine of patent preemption, a fancy legal term that basically means states canโt mess with federal patent law unless they want to be slapped down hard. Amgen argues that capping the price of Enbrel interferes with its ability to recoup the costs of research and development. In other words, they need their monopoly money to keep the lights on. Yet, this raises the question: if they canโt recoup their costs in a reasonable manner, maybe their pricing strategy is the problem, not the state law. Colorado's cap, set to lower the cost of Enbrel from about $53,000 annually to a mere $31,200, would seem like a no-brainer in any sane universe where healthcare is a right, not a privilege. However, in the parallel universe of American healthcare, itโs clear that any attempt to rein in prices is met with fierce resistance from those who profit from the status quo. The court made it clear that the balancing act between profits and access to medications is a task best left to Congress, which has historically shown a talent for doing absolutely nothing. As states like Maryland and Minnesota look to Coloradoโs fight for inspiration, the implications of this ruling could echo far beyond the Rockies. If the federal courts continue to side with corporate interests over the welfare of citizens, weโre left to wonder if the American dream of affordable healthcare is just thatโa dream. The situation is not just indicative of a state versus federal power struggle; itโs a microcosm of the larger debate on how much control corporations should wield over public health. With the stakes as high as they are, one can only hope that Colorado's courage in the face of adversity inspires other states to take a stand. After all, if we canโt cap drug prices, whatโs next? Capping the price of hope?
Still Beats Watergate:
Sponsor success. Continue reading:





